Stock Taper
SCREENER COMPARE ANY 2 STOCKS
CORT
CORCEPT THERAPEUTICS INCORPORATED
NASDAQ
$122.25
▲ UP 0.99% (1.20)

KEY STATISTICS

Market Cap$13.21 B
52w High$123.44
52w Low$28.66
Dividend Yield—
Frequency—
P/E349.29
Volume656.44K
Shares Out.108.10M

COMPANY

LEADERSHIP

Joseph K. Belanoff
CHIEF EXECUTIVE
Joseph K. Belanoff

COMPENSATION 2026

Salary$1,182,333
Stock Awards$0
Incentive Plan Pay$0
All Other Comp.$23,500
Total$15,303,551

ABOUT

SECTOR
Healthcare
WENT PUBLIC
April 14, 2004
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
730

PRICE TARGET

Target High$165.00
Target Low$50.00
Target Median$142.50
Target Consensus$125.33

UPCOMING EARNINGS

DateNov 3, 2026
DayTuesday
Rev. Est.$323.90M
NOV
3
TUE

PRICE

$122.25 ▲ UP 0.99% (+$1.20)
$121$122$122$1239:30 AM10:35 AM11:40 AM12:44 PM1:49 PM2:54 PM3:59 PM122.25

About Corcept Therapeutics Incorporated

https://www.corcept.com ↗

Corcept Therapeutics develops and commercializes drugs for severe metabolic, oncologic, and neuropsychiatric disorders, including Korlym for Cushing's syndrome and investigational treatments like relacorilant and nab-paclitaxel.

INDUSTRY

Medical - Pharmaceuticals

A PRODUCT CORCEPT THERAPEUTICS INCORPORATED IS KNOWN FOR

Korlym
Korlym

Korlym (mifepristone) is Corcept Therapeutics' flagship oral medication for treating hyperglycemia in adults with endogenous Cushing's syndrome and type 2 diabetes or glucose intolerance who are unsuitable for or have failed surgery.

COMPETITORS

COMPETITOR
CRNX COMPARE
NBIX COMPARE
NVS COMPARE
SPRB COMPARE
XERS COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
219
LISTED HERE
26
RANKED BY POSITION SIZE
XSMC.TO
0.64% · 5.8M
VTS.AX
0.01% · 2.9M
FBT
4.08% · 980.9K
SPSM
0.64% · 899.4K
SCHA
0.24% · 453.7K
PJP
4.94% · 215.9K
DFAS
0.16% · 205.3K
JSMD
1.00% · 97.5K
FSMD
0.37% · 95.8K
LFSC
6.95% · 74.9K
PPH
0.67% · 58.3K
ASCE
3.94% · 56.9K
JMEE
0.20% · 49.0K
RECS
0.08% · 42.1K
ABFL
0.18% · 39.9K
FCUS
4.44% · 31.5K
SURI
3.80% · 26.4K
JHSC
0.27% · 21.7K
SGRT
3.76% · 18.1K
SP
SPIT
5.57% · 16.1K
BKMC
0.28% · 15.5K
TQSM.TO
0.25% · 15.2K
ETHO
0.87% · 14.1K
GURU
2.34% · 14.0K
HY
HYP
1.68% · 9.9K
ZSML.TO
0.64% · 9.3K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
68.36%
HOLDERS
650
TOP 12 OF 650 · RANKED BY POSITION SIZE
Blackrock Inc.
16.5M sh · $537.36M
Blackrock, Inc.
12.4M sh · $1.08B
Vanguard Group Inc
9.5M sh · $792.63M
Ingalls & Snyder LLC
7.9M sh · $689.9M
Renaissance Technologies LLC
6.1M sh · $506.09M
Parallel Advisors, LLC
4.0M sh · $160.33M
Fmr LLC
3.3M sh · $290.21M
Blackrock Fund Advisors
3.3M sh · $23.93M
State Street Corp
3.3M sh · $285.15M
Geode Capital Management, LLC
2.7M sh · $109.4M
Aqr Capital Management LLC
2.6M sh · $224.55M
First Trust Advisors LP
2.2M sh · $87.61M

RATINGS SNAPSHOT

Overall rating: B

DCFROEROAD/EP/EP/B
Discounted Cash Flow4
Return On Equity3
Return On Assets4
Debt To Equity4
Price To Earnings1
Price To Book1
Overall Score3

INSIDER TRADES

★
DIRECTOR
MAHONEY DAVID L
Sale · 400 shares
2026-08-18
★
DIRECTOR
MAHONEY DAVID L
Sale · 5.0K shares
2026-08-18
★
DIRECTOR
MAHONEY DAVID L
Sale · 91.2K shares
2026-08-18
★
DIRECTOR
MAHONEY DAVID L
Sale · 7.1K shares
2026-08-18

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 3
OVERWEIGHT 1
UNDERPERFORM 1
5 GRADES IN THE LAST 12 MONTHS
Canaccord Genuity BUY HC Wainwright & Co. BUY Piper Sandler OVERWEIGHT Wolfe Research UNDERPERFORM UBS BUY

SECTORS PEERS

PEERPRICE
JAZZ$254.28COMPARE
HALO$108.17COMPARE
AXSM$207.77COMPARE
CYTK$76.84COMPARE
ABVX$114.95COMPARE
RYTM$110.00COMPARE
CAI$26.27COMPARE
RNA$13.20COMPARE